Merck and TAP Biosystems Finalists for “Best Collaboration Award”
News Oct 08, 2014
TAP Biosystems has announced that TAP Biosystems and Merck have been nominated as co-finalists for two awards at the prestigious 2014 BioProcess International (BPI) Awards. The nominations recognize that the ambr250™ System, developed as a result of the collaboration, is a major advance in bioprocessing technology.
At the BioProcess International Awards, TAP Biosystems and Merck have been selected as finalists in the ‘Best Collaboration Award’ and the ‘Best Technology Application - Upstream Award’ categories from amongst numerous outstanding industrial collaborations for their partnership to develop the powerful ambr250 automated mini bioreactor system.
The high-throughput ambr250, co-developed with Merck, has the flexibility to culture mammalian lines, including CHO, or microbial cells, such as Pichia pastoris and E.coli, in single-use, stirred bioreactors utilizing continuous pumped feeds. This means using the ambr250 it is now possible to fully evaluate the process characteristics of large-scale bioreactors and fermenters in weeks rather than months, making the system a significant breakthrough in bioprocessing technology.
For details of all the finalists in the 2014 BPI awards, please go to http://www.bioprocessintl.com/wp-content/uploads/2014/10/BPI-Awards_Finalists_2014.pdf.
Mwai Ngibuini, ambr250 Product Manager at TAP Biosystems commented: “We’re honoured to be shortlisted with Merck for not one, but two BPI awards from such an amazing line-up of bioprocessing advances. Being recognised in these celebrated awards is a great accolade, and further supports the use of ambr250 technology as an excellent strategy for optimizing production of antibody and protein-based therapeutics to pharma and biotech world-wide.”
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE